Exchange of Associated Factors Directs a Switch in HBO1 Acetyltransferase Histone Tail Specificity
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Functional Roles of Bromodomain Proteins in Cancer
cancers Review Functional Roles of Bromodomain Proteins in Cancer Samuel P. Boyson 1,2, Cong Gao 3, Kathleen Quinn 2,3, Joseph Boyd 3, Hana Paculova 3 , Seth Frietze 3,4,* and Karen C. Glass 1,2,4,* 1 Department of Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, Colchester, VT 05446, USA; [email protected] 2 Department of Pharmacology, Larner College of Medicine, University of Vermont, Burlington, VT 05405, USA; [email protected] 3 Department of Biomedical and Health Sciences, University of Vermont, Burlington, VT 05405, USA; [email protected] (C.G.); [email protected] (J.B.); [email protected] (H.P.) 4 University of Vermont Cancer Center, Burlington, VT 05405, USA * Correspondence: [email protected] (S.F.); [email protected] (K.C.G.) Simple Summary: This review provides an in depth analysis of the role of bromodomain-containing proteins in cancer development. As readers of acetylated lysine on nucleosomal histones, bromod- omain proteins are poised to activate gene expression, and often promote cancer progression. We examined changes in gene expression patterns that are observed in bromodomain-containing proteins and associated with specific cancer types. We also mapped the protein–protein interaction network for the human bromodomain-containing proteins, discuss the cellular roles of these epigenetic regu- lators as part of nine different functional groups, and identify bromodomain-specific mechanisms in cancer development. Lastly, we summarize emerging strategies to target bromodomain proteins in cancer therapy, including those that may be essential for overcoming resistance. Overall, this review provides a timely discussion of the different mechanisms of bromodomain-containing pro- Citation: Boyson, S.P.; Gao, C.; teins in cancer, and an updated assessment of their utility as a therapeutic target for a variety of Quinn, K.; Boyd, J.; Paculova, H.; cancer subtypes. -
Geminin Prevents DNA Damage in Vagal Neural Crest Cells to Ensure Normal Enteric Neurogenesis Chrysoula Konstantinidou1,3, Stavros Taraviras2* and Vassilis Pachnis1*
Konstantinidou et al. BMC Biology (2016) 14:94 DOI 10.1186/s12915-016-0314-x RESEARCH ARTICLE Open Access Geminin prevents DNA damage in vagal neural crest cells to ensure normal enteric neurogenesis Chrysoula Konstantinidou1,3, Stavros Taraviras2* and Vassilis Pachnis1* Abstract Background: In vertebrate organisms, the neural crest (NC) gives rise to multipotential and highly migratory progenitors which are distributed throughout the embryo and generate, among other structures, the peripheral nervous system, including the intrinsic neuroglial networks of the gut, i.e. the enteric nervous system (ENS). The majority of enteric neurons and glia originate from vagal NC-derived progenitors which invade the foregut mesenchyme and migrate rostro-caudally to colonise the entire length of the gut. Although the migratory behaviour of NC cells has been studied extensively, it remains unclear how their properties and response to microenvironment change as they navigate through complex cellular terrains to reach their target embryonic sites. Results: Using conditional gene inactivation in mice we demonstrate here that the cell cycle-dependent protein Geminin (Gem) is critical for the survival of ENS progenitors in a stage-dependent manner. Gem deletion in early ENS progenitors (prior to foregut invasion) resulted in cell-autonomous activation of DNA damage response and p53-dependent apoptosis, leading to severe intestinal aganglionosis. In contrast, ablation of Gem shortly after ENS progenitors had invaded the embryonic gut did not result in discernible survival or migratory deficits. In contrast to other developmental systems, we obtained no evidence for a role of Gem in commitment or differentiation of ENS lineages. The stage-dependent resistance of ENS progenitors to mutation-induced genotoxic stress was further supported by the enhanced survival of post gut invasion ENS lineages to γ-irradiation relative to their predecessors. -
Overexpression of Androgen Receptor in Prostate Cancer
ALFONSO URBANUCCI Overexpression of Androgen Receptor in Prostate Cancer ACADEMIC DISSERTATION To be presented, with the permission of the board of Institute of Biomedical Technology of the University of Tampere, for public discussion in the Jarmo Visakorpi Auditorium, of the Arvo Building, Lääkärinkatu 1, Tampere, on January 20th, 2012, at 12 o’clock. UNIVERSITY OF TAMPERE ACADEMIC DISSERTATION University of Tampere, Institute of Biomedical Technology and BioMediTech Tampere University Hospital, Laboratory Centre Graduate Program in Biomedicine and Biotechnology (TGPBB) Finland Supervised by Reviewed by Professor Tapio Visakorpi Docent Auli Karhu University of Tampere University of Helsinki Finland Finland Docent Noora Kotaja University of Turku Finland Copyright ©2012 Tampere University Press and the author Distribution Tel. +358 40 190 9800 Bookshop TAJU Fax +358 3 3551 7685 P.O. Box 617 [email protected] 33014 University of Tampere www.uta.fi/taju Finland http://granum.uta.fi Cover design by Mikko Reinikka Acta Universitatis Tamperensis 1693 Acta Electronica Universitatis Tamperensis 1159 ISBN 978-951-44-8685-2 (print) ISBN 978-951-44-8686-9 (pdf) ISSN-L 1455-1616 ISSN 1456-954X ISSN 1455-1616 http://acta.uta.fi Tampereen Yliopistopaino Oy – Juvenes Print Tampere 2012 CONTENTS ABBREVIATIONS ..................................................................................................... 5 ABSTRACT ................................................................................................................ 7 SINTESI ..................................................................................................................... -
Androgen Receptor Interacting Proteins and Coregulators Table
ANDROGEN RECEPTOR INTERACTING PROTEINS AND COREGULATORS TABLE Compiled by: Lenore K. Beitel, Ph.D. Lady Davis Institute for Medical Research 3755 Cote Ste Catherine Rd, Montreal, Quebec H3T 1E2 Canada Telephone: 514-340-8260 Fax: 514-340-7502 E-Mail: [email protected] Internet: http://androgendb.mcgill.ca Date of this version: 2010-08-03 (includes articles published as of 2009-12-31) Table Legend: Gene: Official symbol with hyperlink to NCBI Entrez Gene entry Protein: Protein name Preferred Name: NCBI Entrez Gene preferred name and alternate names Function: General protein function, categorized as in Heemers HV and Tindall DJ. Endocrine Reviews 28: 778-808, 2007. Coregulator: CoA, coactivator; coR, corepressor; -, not reported/no effect Interactn: Type of interaction. Direct, interacts directly with androgen receptor (AR); indirect, indirect interaction; -, not reported Domain: Interacts with specified AR domain. FL-AR, full-length AR; NTD, N-terminal domain; DBD, DNA-binding domain; h, hinge; LBD, ligand-binding domain; C-term, C-terminal; -, not reported References: Selected references with hyperlink to PubMed abstract. Note: Due to space limitations, all references for each AR-interacting protein/coregulator could not be cited. The reader is advised to consult PubMed for additional references. Also known as: Alternate gene names Gene Protein Preferred Name Function Coregulator Interactn Domain References Also known as AATF AATF/Che-1 apoptosis cell cycle coA direct FL-AR Leister P et al. Signal Transduction 3:17-25, 2003 DED; CHE1; antagonizing regulator Burgdorf S et al. J Biol Chem 279:17524-17534, 2004 CHE-1; AATF transcription factor ACTB actin, beta actin, cytoplasmic 1; cytoskeletal coA - - Ting HJ et al. -
Recognition of Cancer Mutations in Histone H3K36 by Epigenetic Writers and Readers Brianna J
EPIGENETICS https://doi.org/10.1080/15592294.2018.1503491 REVIEW Recognition of cancer mutations in histone H3K36 by epigenetic writers and readers Brianna J. Kleina, Krzysztof Krajewski b, Susana Restrepoa, Peter W. Lewis c, Brian D. Strahlb, and Tatiana G. Kutateladzea aDepartment of Pharmacology, University of Colorado School of Medicine, Aurora, CO, USA; bDepartment of Biochemistry & Biophysics, The University of North Carolina School of Medicine, Chapel Hill, NC, USA; cWisconsin Institute for Discovery, University of Wisconsin, Madison, WI, USA ABSTRACT ARTICLE HISTORY Histone posttranslational modifications control the organization and function of chromatin. In Received 30 May 2018 particular, methylation of lysine 36 in histone H3 (H3K36me) has been shown to mediate gene Revised 1 July 2018 transcription, DNA repair, cell cycle regulation, and pre-mRNA splicing. Notably, mutations at or Accepted 12 July 2018 near this residue have been causally linked to the development of several human cancers. These KEYWORDS observations have helped to illuminate the role of histones themselves in disease and to clarify Histone; H3K36M; cancer; the mechanisms by which they acquire oncogenic properties. This perspective focuses on recent PTM; methylation advances in discovery and characterization of histone H3 mutations that impact H3K36 methyla- tion. We also highlight findings that the common cancer-related substitution of H3K36 to methionine (H3K36M) disturbs functions of not only H3K36me-writing enzymes but also H3K36me-specific readers. The latter case suggests that the oncogenic effects could also be linked to the inability of readers to engage H3K36M. Introduction from yeast to humans and has been shown to have a variety of functions that range from the control Histone proteins are main components of the of gene transcription and DNA repair, to cell cycle nucleosome, the fundamental building block of regulation and nutrient stress response [8]. -
Rabbit Anti-Phospho-MCM2-SL18262R-FITC
SunLong Biotech Co.,LTD Tel: 0086-571- 56623320 Fax:0086-571- 56623318 E-mail:[email protected] www.sunlongbiotech.com Rabbit Anti-phospho-MCM2 SL18262R-FITC Product Name: Anti-phospho-MCM2 (Ser27)/FITC Chinese Name: FITC标记的磷酸化MCM2蛋白抗体 MCM4 (phospho S27); MCM2(phospho-Ser27); MCM2(phospho Ser27); MCM2 (phospho S27); p-MCM2(Ser27); p-MCM2(S27); MCM2 (phospho S27); p-MCM2 (phospho S27); BM28; CCNL 1; CCNL1; CDC like 1; CDC like-1; cdc19; CDCL 1; CDCL1; Cell devision cycle like 1; Cyclin like 1; cyclin like-1; D3S3194; DNA replication licensing factor MCM2; KIAA0030; MCM 2; MCM2; MCM2 minichromosome maintenance deficient 2 mitotin; MCM2 minichromosome Alias: maintenance deficient 2 mitotin (S. cerevisiae); MCM2 minichromosome maintenance deficient 2, mitotin; MCM2_HUMAN; MCM2_MOUSE; MGC10606; Minichromosome maintenance complex component 2; Minichromosome maintenance deficient 2 (mitotin); Minichromosome maintenance deficient 2 mitotin; Minichromosome maintenance protein 2; Minichromosome maintenance protein 2 homolog; Mitotin; Nuclear protein BM28; OTTHUMP00000216047; OTTHUMP00000216050. Organism Species: Rabbit Clonality: Polyclonalwww.sunlongbiotech.com React Species: Human,Mouse,Rat,Dog,Pig,Rabbit, ICC=1:50-200IF=1:50-200 Applications: not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. Molecular weight: 101kDa Form: Lyophilized or Liquid Concentration: 1mg/ml immunogen: phosphopeptide derived from human MCM2 around the phosphorylation site of Ser27 Lsotype: IgG Purification: affinity purified by Protein A Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. Storage: Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. -
Further Delineation of the Clinical Spectrum of KAT6B Disorders and Allelic Series of Pathogenic Variants
ARTICLE © American College of Medical Genetics and Genomics Further delineation of the clinical spectrum of KAT6B disorders and allelic series of pathogenic variants Li Xin Zhang1, Gabrielle Lemire, MD2, Claudia Gonzaga-Jauregui, PhD3, Sirinart Molidperee, Gr. Cert1, Carolina Galaz-Montoya, MD3, David S. Liu, MD3, Alain Verloes, MD PhD4, Amelle G. Shillington, DO5, Kosuke Izumi, MD PhD6, Alyssa L. Ritter, MS LCGC7, Beth Keena, MS LCGC6, Elaine Zackai, MD7,8, Dong Li, PhD9, Elizabeth Bhoj, MD PhD7, Jennifer M. Tarpinian, MS CGC10, Emma Bedoukian, MS LCGC10, Mary K. Kukolich, MD11, A. Micheil Innes, MD12, Grace U. Ediae, BSc13, Sarah L. Sawyer, MD PhD14, Karippoth Mohandas Nair, MD15, Para Chottil Soumya, MD15, Kinattinkara R. Subbaraman, MD15, Frank J. Probst, MD PhD3,16, Jennifer A. Bassetti, MD3,16, Reid V. Sutton, MD3,16, Richard A. Gibbs, PhD3, Chester Brown, MD PhD17, Philip M. Boone, MD PhD18, Ingrid A. Holm, MD MPH18, Marco Tartaglia, PhD19, Giovanni Battista Ferrero, MD PhD20, Marcello Niceta, MD PhD19, Maria Lisa Dentici, MD19, Francesca Clementina Radio, MD PhD19, Boris Keren, MD21, Constance F. Wells, MD22, Christine Coubes, MD22, Annie Laquerrière, MD PhD23, Jacqueline Aziza, MD24, Charlotte Dubucs, MD24, Sheela Nampoothiri, MD25, David Mowat, MD26, Millan S. Patel, MD27, Ana Bracho, MD28, Francisco Cammarata-Scalisi, MD29, Alper Gezdirici, MD30, Alberto Fernandez-Jaen, MD31, Natalie Hauser, MD32, Yuri A. Zarate, MD33, Katherine A. Bosanko, MS CGC33, Klaus Dieterich, MD PhD34, John C. Carey, MD MPH35, Jessica X. Chong, PhD36,37, Deborah A. Nickerson, PhD37,38, Michael J. Bamshad, MD36,37, Brendan H. Lee, MD PhD3, Xiang-Jiao Yang, PhD39, James R. -
Investigation of the Interplay Between SKP2, CDT1 and Geminin in Cancer Cells
1 Investigation of the interplay between SKP2, CDT1 and Geminin in cancer cells 2 3 Andrea Ballabeni¶*, Raffaella Zamponi§ 4 5 ¶Department of Systems Biology, Harvard Medical School, Boston, MA, USA 6 (Current affiliation: Harvard School of Public Health, Boston, MA, USA) s 7 t n i 8 §Department of Experimental Oncology, European Institute of Oncology, Milan, Italy r P 9 (Current affiliation: Novartis Institutes of Biomedical research, Cambridge, MA, USA) e r 10 P 11 *Corresponding author E-mail: [email protected], [email protected] 12 13 Abstract 14 Geminin has a dual role in the regulation of DNA replication: it inhibits replication factor CDT1 15 activity during the G2 phase of the cell cycle and promotes its accumulation at the G2/M 16 transition. In this way Geminin prevents DNA re-replication during G2 phase and ensures that 17 DNA replication is efficiently executed in the next S phase. CDT1 was shown to associate with 18 SKP2, the substrate recognition factor of the SCF ubiquitin ligase complex. We investigated the 19 interplay between these three proteins in cancer cell lines. We show that Geminin, CDT1 and 20 SKP2 could possibly form a complex and propose the putative regions of CDT1 and Geminin 21 involved in the binding. We also show that, despite the physical interaction, SKP2 depletion does 22 not substantially affect CDT1 and Geminin protein levels. Moreover, we show that while 1 PeerJ PrePrints | http://dx.doi.org/10.7287/peerj.preprints.794v1 | CC-BY 4.0 Open Access | rec: 16 Jan 2015, publ: 16 Jan 2015 1 Geminin and CDT1 levels fluctuate, SKP2 levels, differently than in normal cells, are almost 2 steady during the cell cycle of the tested cancer cells. -
Geminin-Deficient Neural Stem Cells Exhibit Normal Cell Division and Normal Neurogenesis
Geminin-Deficient Neural Stem Cells Exhibit Normal Cell Division and Normal Neurogenesis Kathryn M. Schultz1,2, Ghazal Banisadr4., Ruben O. Lastra1,2., Tammy McGuire5, John A. Kessler5, Richard J. Miller4, Thomas J. McGarry1,2,3* 1 Feinberg Cardiovascular Research Institute, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States of America, 2 Department of Cell and Molecular Biology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States of America, 3 Robert H. Lurie Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States of America, 4 Department of Molecular Pharmacology and Biological Chemistry, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States of America, 5 Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States of America Abstract Neural stem cells (NSCs) are the progenitors of neurons and glial cells during both embryonic development and adult life. The unstable regulatory protein Geminin (Gmnn) is thought to maintain neural stem cells in an undifferentiated state while they proliferate. Geminin inhibits neuronal differentiation in cultured cells by antagonizing interactions between the chromatin remodeling protein Brg1 and the neural-specific transcription factors Neurogenin and NeuroD. Geminin is widely expressed in the CNS during throughout embryonic development, and Geminin expression is down-regulated when neuronal precursor cells undergo terminal differentiation. Over-expression of Geminin in gastrula-stage Xenopus embryos can expand the size of the neural plate. The role of Geminin in regulating vertebrate neurogenesis in vivo has not been rigorously examined. To address this question, we created a strain of Nestin-Cre/Gmnnfl/fl mice in which the Geminin gene was specifically deleted from NSCs. -
Anti-Geminin Antibody (Clone 1A8) Mouse Anti Human Monoclonal Antibody Catalog # ALS17716
10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 Anti-Geminin Antibody (clone 1A8) Mouse Anti Human Monoclonal Antibody Catalog # ALS17716 Specification Anti-Geminin Antibody (clone 1A8) - Product Information Application WB, IHC-P, IF, E Primary Accession O75496 Predicted Human Host Mouse Clonality Monoclonal Isotype IgG1,k Calculated MW 23565 Anti-Geminin Antibody (clone 1A8) - Additional Information Gene ID 51053 Alias Symbol GMNN Other Names GMNN, Geminin Target/Specificity Human Geminin Reconstitution & Storage Protein A purified Precautions Anti-Geminin Antibody (clone 1A8) is for research use only and not for use in diagnostic or therapeutic procedures. Anti-Geminin Antibody (clone 1A8) - Protein Information Name GMNN Function Inhibits DNA replication by preventing the incorporation of MCM complex into pre-replication complex (pre-RC) (PubMed:<a href="http://www.uniprot.org/c itations/9635433" target="_blank">9635433</a>, PubMed:<a href="http://www.uniprot.org/ci tations/14993212" target="_blank">14993212</a>, Page 1/3 10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 PubMed:<a href="http://www.uniprot.org/ci tations/20129055" target="_blank">20129055</a>, PubMed:<a href="http://www.uniprot.org/ci tations/24064211" target="_blank">24064211</a>). It is degraded during the mitotic phase of the cell cycle (PubMed:<a href="http://www.uni prot.org/citations/9635433" target="_blank">9635433</a>, PubMed:<a href="http://www.uniprot.org/ci tations/14993212" target="_blank">14993212</a>, PubMed:<a href="http://www.uniprot.org/ci tations/24064211" target="_blank">24064211</a>). -
Geminin Deploys Multiple Mechanisms to Regulate Cdt1 Before Cell Division Thus Ensuring the Proper Execution of DNA Replication
Geminin deploys multiple mechanisms to regulate Cdt1 before cell division thus ensuring the proper execution of DNA replication Andrea Ballabenia, Raffaella Zamponib, Jodene K. Moorea, Kristian Helinc,d, and Marc W. Kirschnera,1 aDepartment of Systems Biology, Harvard Medical School, Boston, MA 02115; bNovartis Institutes for Biomedical Research, Cambridge, MA 02139; cBiotech Research and Innovation Centre and dCentre for Epigenetics, University of Copenhagen, 2200 Copenhagen, Denmark Contributed by Marc W. Kirschner, June 7, 2013 (sent for review March 4, 2013) Cdc10-dependent transcript 1 (Cdt1) is an essential DNA replication the initiation of S phase and its duration. We show that although protein whose accumulation at the end of the cell cycle promotes Cdt1 protein accumulates in G2 phase, it still turns over very the formation of pre-replicative complexes and replication in the quickly and that to produce high Cdt1 levels when cells exit next cell cycle. Geminin is thought to be involved in licensing rep- mitosis into G1, the accumulation in G2 must overcome degra- lication by promoting the accumulation of Cdt1 in mitosis, because dation. This regulation is a product of Geminin’s positive regu- decreasing the Geminin levels prevents Cdt1 accumulation and lation of Cdt1 protein and RNA in the preceding G2 phase. impairs DNA replication. Geminin is known to inhibit Cdt1 func- Degradation of Cdt1 is not a consequence of DNA damage, be- tion; its depletion during G2 leads to DNA rereplication and check- cause Cdt1 levels decrease upon Geminin depletion even in point activation. Here we show that, despite rapid Cdt1 protein presence of inhibitors of DNA synthesis. -
Quaternary Structure of the Human Cdt1-Geminin Complex Regulates DNA Replication Licensing
Quaternary structure of the human Cdt1-Geminin complex regulates DNA replication licensing V. De Marcoa,1, P. J. Gillespieb,2,A.Lib,2,3, N. Karantzelisc, E. Christodouloua,1, R. Klompmakerd, S. van Gerwena, A. Fisha, M. V. Petoukhove, M. S. Iliouf,4, Z. Lygerouf, R. H. Medemad, J. J. Blowb,5, D. I. Svergune, S. Taravirasc, and A. Perrakisa,5 aDepartment of Biochemistry, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands; bWellcome Trust Centre for Gene Regulation and Expression, College of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom; Departments of cPharmacology and fBiology, Medical School, University of Patras, 26500 Rio, Patras, Greece; dDepartment of Medical Oncology and Cancer Genomics Center, Laboratory of Experimental Oncology, University Medical Center Utrecht, Universiteitsweg 100, 3584CG Utrecht, The Netherlands; and eEuropean Molecular Biology Laboratory, Hamburg Outstation, Notkestrasse 85, D-22603 Hamburg, Germany Edited by John Kuriyan, University of California, Berkeley, CA, and approved October 2, 2009 (received for review May 14, 2009) All organisms need to ensure that no DNA segments are rerepli- the remainder becomes inactivated and incapable of inhibiting Cdt1 cated in a single cell cycle. Eukaryotes achieve this through a (16–18). The remaining Geminin gets reactivated in the next cell process called origin licensing, which involves tight spatiotemporal cycle, through a mechanism that is not well understood, but is control of the assembly of prereplicative complexes (pre-RCs) onto dependent on the nuclear import of Geminin, which restores its chromatin. Cdt1 is a key component and crucial regulator of pre-RC ability to block Cdt1 (16, 19, 20).